[{"indications": "Indications\u00a0mild inflammatory skin disorders such as eczemas\r\n(but for over-the-counter preparations, see below); nappy rash (see\r\nalso section 13.2.2)", "name": "HYDROCORTISONE Proprietary hydrocortisone preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "HYDROCORTISONE", "Proprietary hydrocortisone preparations"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5847.htm", "doses": ["Apply thinly 1\u20132 times daily", "Name[Mildison\u00ae (Astellas) ] Lipocream, hydrocortisone 1%, net price 30\u00a0g = \u00a31.71. \r\n    Label:\r\n    28, counselling, application. Potency: mildExcipients  include cetostearyl\r\nalcohol, hydroxybenzoates (parabens)"]}, {"indications": "Indications\u00a0mild inflammatory skin disorders such as eczemas\r\n(but for over-the-counter preparations, see below); nappy rash (see\r\nalso section 13.2.2)", "name": "HYDROCORTISONE With antimicrobials", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "HYDROCORTISONE", "With antimicrobials"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5856.htm", "doses": ["Apply thinly 1\u20132 times daily", "Name[Daktacort\u00ae (Janssen) ] Cream, hydrocortisone 1%, miconazole nitrate 2%, net price 30\u00a0g = \u00a32.49. \r\n    Label:\r\n    28, counselling, application. Potency: mildExcipients  include butylated\r\nhydroxyanisole, disodium edetateInteractions: Appendix 1 (miconazole)\u2014see miconazole nitrateDental prescribing on NHS\u00a0May be prescribed as\r\nMiconazole and Hydrocortisone Cream for max. 7 daysNote\u00a0A 15-g tube is on sale to the public for\r\nthe treatment of athlete\u2019s foot and candidal intertrigo\nOintment, hydrocortisone 1%, miconazole nitrate 2%, net price 30\u00a0g = \u00a32.50. \r\n    Label:\r\n    28, counselling, application. Potency: mildExcipients  none as listed in section 13.1.3Interactions: Appendix 1 (miconazole)\u2014see miconazole nitrateDental prescribing on NHS\u00a0May be prescribed as\r\nMiconazole and Hydrocortisone Ointment for max. 7 days"]}, {"indications": "Indications\u00a0ulcerative colitis, proctitis, proctosigmoiditis", "name": "HYDROCORTISONE - CHRONIC BOWEL DISORDERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.2 Corticosteroids", "HYDROCORTISONE"], "cautions": "Cautions\u00a0section 6.3.2; systemic absorption may occur; prolonged\r\nuse should be avoided", "side-effects": "Side-effects\u00a0section 6.3.2; also local irritation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2180.htm", "doses": ["By rectum see preparations", "initially 1 metered application (125\u00a0mg hydrocortisone acetate) inserted into the rectum once or twice\r\ndaily for 2\u20133 weeks, then once on alternate days; child 2\u201318 years see BNF for Children"]}, {"indications": "Indications\u00a0mild inflammatory skin disorders such as eczemas\r\n(but for over-the-counter preparations, see below); nappy rash (see\r\nalso section 13.2.2)", "name": "HYDROCORTISONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "HYDROCORTISONE"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/15416.htm", "doses": ["Apply thinly 1\u20132 times daily"]}, {"indications": "Indications\u00a0local treatment of inflammation (short-term)", "name": "HYDROCORTISONE ACETATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.4 Corticosteroids and other anti-inflammatory preparations", "11.4.1 Corticosteroids"], "cautions": "Cautions\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\nTopical corticosteroids  are applied frequently for the first 24\u201348 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:a \u2018red eye\u2019, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;\u2018steroid glaucoma\u2019 can follow the use of corticosteroid eye preparations in susceptible individuals;a \u2018steroid cataract\u2019 can follow prolonged use.", "side-effects": "Side-effects\u00a0\n(From 11.4.1 Corticosteroids: British National Formulary)\n11.4.1 Corticosteroids", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5433.htm", "doses": ["Apply eye drops every 30\u201360 minutes until controlled then\r\nreduce frequency to every 4 hours"]}, {"indications": "Indications\u00a0mild inflammatory skin disorders such as eczemas\r\n(but for over-the-counter preparations, see below); nappy rash (see\r\nalso section 13.2.2)", "name": "HYDROCORTISONE - TOPICAL CORTICOSTEROIDS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "HYDROCORTISONE"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/15416.htm", "doses": ["Apply thinly 1\u20132 times daily"]}, {"indications": "Indications\u00a0severe inflammatory skin disorders such as eczemas\r\nunresponsive to less potent corticosteroids; psoriasis,\r\n\n(From 13.4 Topical corticosteroids: British National Formulary)\n13.4 Topical corticosteroids", "name": "HYDROCORTISONE BUTYRATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5868.htm", "doses": ["Apply thinly 1\u20132 times daily"]}, {"indications": "Indications\u00a0eczematous inflammation in otitis externa (see notes\r\nabove)", "name": "HYDROCORTISONE With antibacterial", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "12 Ear, nose, and oropharynx", "12.1 Drugs acting on the ear", "12.1.1 Otitis externa", "Anti-inflammatory preparations", "Corticosteroids", "HYDROCORTISONE", "With antibacterial"], "cautions": "Cautions\u00a0\n(From Corticosteroids: British National Formulary)\nCautions\u00a0Prolonged use of topical corticosteroid ear preparations should be avoided.", "side-effects": "Side-effects\u00a0\n(From Corticosteroids: British National Formulary)\nSide-effects\u00a0Local sensitivity reactions may occur.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31411.htm", "doses": ["Name[Otosporin\u00ae (GSK) ] Ear drops, hydrocortisone 1%, neomycin sulphate 3400\u00a0units, polymyxin B sulphate 10\u00a0000\u00a0units/mL.\r\nNet price 5\u00a0mL = \u00a32.00; 10\u00a0mL = \u00a34.00Excipients  include cetostearyl alcohol, hydroxybenzoates (parabens), polysorbate 20Dose\u00a0adult and child over 3 years, ear, apply 3 drops\r\n3\u20134 times daily"]}, {"indications": "Indications\u00a0ulcerative colitis, proctitis, proctosigmoiditis", "name": "HYDROCORTISONE - CORTICOSTEROIDS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.2 Corticosteroids", "HYDROCORTISONE"], "cautions": "Cautions\u00a0section 6.3.2; systemic absorption may occur; prolonged\r\nuse should be avoided", "side-effects": "Side-effects\u00a0section 6.3.2; also local irritation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2180.htm", "doses": ["By rectum see preparations", "initially 1 metered application (125\u00a0mg hydrocortisone acetate) inserted into the rectum once or twice\r\ndaily for 2\u20133 weeks, then once on alternate days; child 2\u201318 years see BNF for Children"]}, {"indications": "Indications\u00a0adrenocortical insufficiency (section 6.3.1); shock; see also notes above; hypersensitivity\r\nreactions e.g. anaphylaxis and angioedema (section 3.4.3); asthma (section 3.1); severe inflammatory bowel disease\r\n(section 1.5); haemorrhoids (section 1.7.2); rheumatic\r\ndisease (section 10.1.2); eye (section 11.4.1); skin (section 13.4)", "name": "HYDROCORTISONE - GLUCOCORTICOID THERAPY", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.3 Corticosteroids", "6.3.2 Glucocorticoid therapy", "HYDROCORTISONE"], "cautions": "Cautions\u00a0\n(From Cautions and contra-indications of corticosteroids: British National Formulary)\nCautions and contra-indications of corticosteroids", "side-effects": "Side-effects\u00a0\n(From Side-effects of corticosteroids: British National Formulary)\nSide-effects of corticosteroids; also phosphate ester associated\r\nwith paraesthesia and pain (particularly in the perineal region)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200895.htm", "doses": ["By mouth, replacement therapy, 20\u201330\u00a0mg\r\ndaily in divided doses\u2014see section 6.3.1; child 1 month\u201318\r\nyears see BNF for Children", "By intramuscular injection or slow intravenous injection or infusion, 100\u2013500\u00a0mg, 3\u20134 times in 24 hours or as required; child by slow intravenous injection up to 1 year 25\u00a0mg, 1\u20135 years 50\u00a0mg, 6\u201312 years 100\u00a0mg"], "pregnancy": "Pregnancy\u00a0\n(From Pregnancy and breast-feeding: British National Formulary)\nPregnancy and breast-feeding"}, {"indications": "Indications\u00a0mild inflammatory skin disorders such as eczemas\r\n(but for over-the-counter preparations, see below); nappy rash (see\r\nalso section 13.2.2)", "name": "HYDROCORTISONE Compound preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.4 Topical corticosteroids", "HYDROCORTISONE", "Compound preparations"], "cautions": "Cautions\u00a0\n(From 13.4 Topical corticosteroids: British National Formulary)\nCautions\u00a0Avoid prolonged use of a topical corticosteroid on the face (and keep away from eyes). In children avoid prolonged use and use potent or very potent corticosteroids under specialist supervision; extreme caution is required in dermatoses of infancy including nappy rash\u2014treatment should be limited to 5\u20137 days.Psoriasis\u00a0The use of potent or very potent corticosteroids in psoriasis can result in rebound relapse, development of generalised pustular psoriasis, and local and systemic toxicity.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5850.htm", "doses": ["Apply thinly 1\u20132 times daily", "Name[Calmurid HC\u00ae (Galderma) ] Cream, hydrocortisone 1%, urea 10%, lactic acid 5%, net price 100\u00a0g = \u00a38.76. \r\n    Label:\r\n    28, counselling, application. Potency: moderateExcipients  none as listed in section 13.1.3Note\u00a0If stinging occurs, manufacturer advises\r\ndilute to half-strength with aqueous cream for 1 week then transfer\r\nto undiluted preparation (but see section\r\n13.1.1 for advice to avoid dilution where possible)"]}]